Pharma Marketing Blog represents the opinions of
John Mack
Publisher of
Pharma Marketing News.
We accept advertising relevant to the interests of our members.
For more information, see:
Operated by:
VirSci Corporation
PO Box 760
Newtown, PA 18940
215-504-4164
215-504-5739 (FAX)
E-mail: infovirsci@virsci.com
My Humble Opinion
|
Other People's Opinion
|
| A "Must Read" Blog for Insiders. -- Wall Street Journal | A bi-weekly podcast. Listen and call-in live online or download to your iPod! |
| Also see Pharma Marketing News OpEd Pieces |
alli Marketer Explains "Treatment Effects"Posted: July 16, 2007Back on June 12, 2007, I noted that the alli marketers applied newspeak principles to direct-to-consumer (DTC) advertising by referring to the drug's oily spotting side effects as "treatment effects." (See Alli Newspeak: Oily Spotting is "Treatment Effect".) Joe Cadle -- official alli marketing director and self-proclaimed "Mr. Marketing Guy" over at the alliConnect blog -- argues that "calling them side effects is actually misleading." To see his "actual" logic and get some thoughts on pharma OTC vs Rx product blogging, see today's post to Pharma Marketing Blog. For more posts in related topic areas, see: If you wish to receive notice by email whenever a post is made to Pharma Marketing Blog, please subscribe.
|
Special Supplement ePharma Marketing
The selection of articles in this Special Supplement to Pharma Marketing News was chosen to give you a better perspective on pharma eMarketing. Included are real world case studies that illustrate the advantages of eMarketing such as depth of information, interaction, relationship building and superior customer engagement.
Order and pay for this Special Supplement now using your credit card ONLY $29.95
If you wish to pay by check or credit card off-line, please use: |
